Updated Overall Survival From Stage 1 of PRESERVE-003

Name: Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Uploaded: 2026-09-22T04:00:00+00:00
Duration: 3 min 48 s
Description: In this video brief, Dr. Byoung Chul Cho reviews updated overall survival findings from stage 1 of the phase 3 PRESERVE-003 trial, which evaluates gotistob

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Integrating Molecular Testing into NSCLC Care
Integrating Molecular Testing into NSCLC Care
Project Oncology®
Integrating Molecular Testing into NSCLC Care
Geoffrey Oxnard, MD
- Geoffrey Oxnard, MD
A New Era of Hope in Non-Small Cell Lung Cancer Care
A New Era of Hope in Non-Small Cell Lung Cancer Care
Project Oncology®
A New Era of Hope in Non-Small Cell Lung Cancer Care
Geoffrey Oxnard, MD
- Geoffrey Oxnard, MD
Smarter Screening for Non-Small Cell Lung Cancer
Smarter Screening for Non-Small Cell Lung Cancer
Project Oncology®
Smarter Screening for Non-Small Cell Lung Cancer
Jobelle Baldonado, MD
- Jobelle Baldonado, MD
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Project Oncology®
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Laura Alder, MD
- Laura Alder, MD